{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.429","value":"0.0252"}]}],"title":"Pre-dose Cycle 1 (n=303)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.9","value":"74.2"}]}],"title":"Pre-dose Cycle 2 (n=269)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.5","value":"120.0"}]}],"title":"Pre-dose Cycle 3 (n=146)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.7","value":"147.0"}]}],"title":"Pre-dose Cycle 4 (n=186)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"76.1","value":"188.0"}]}],"title":"Pre-dose Cycle 8 (n=108)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"OG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"paramType":"MEAN","populationDescription":"Cohort 2 PK evaluable population. Here, number of participants analyzed = participants who were evaluable for this outcome. \"n\" = participants who were evaluable at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hours) on Day 1 of Cycles 1, 2, 3, 4, 8 (Cycle length = 21 days)","title":"Minimum Serum Concentration (Cmin) of Atezolizumab","type":"SECONDARY","unitOfMeasure":"mcg/mL"}